Pharmaceutical use and costs in patients with coronary artery disease, using Australian observational data.
Victoria McCreanorWilliam A ParsonageDavid C WhitemanCatherine M OlsenAdrian Gerard BarnettNicholas GravesPublished in: BMJ open (2019)
Our results suggest that despite the common expectation that the burden of medical therapy is reduced following coronary stent insertion for stable coronary artery disease, this does not occur in practice. Many patients also appear to continue DAPT longer than guidelines recommend, which may put them at unnecessarily elevated risk of bleeding events.
Keyphrases
- coronary artery disease
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- coronary artery
- primary care
- prognostic factors
- electronic health record
- type diabetes
- coronary artery bypass grafting
- aortic stenosis
- clinical practice
- big data
- heart failure
- cardiovascular disease
- patient reported outcomes
- deep learning
- risk factors
- mesenchymal stem cells
- patient reported
- data analysis
- transcatheter aortic valve replacement